Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 01:18 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Sildenafil for Chronic Obstructive Pulmonary Disease (COPD) Associated Pulmonary Hypertension
NCT00730067 · University of Aarhus · PHASE4 · withdrawn · last registry update 2012-08-23 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “As a single center, it was not possible to recruit enough patients with pulmonary hypertension” | – | Registry record, University of Aarhus |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PDE5A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2013-05-17Results posted on the registry: Actelion, Bosentan + Sildenafil (NCT00433329)
- 2013-04-04Phase 3 first posted: Eli Lilly and Company, Tadalafil + Placebo (NCT01824290)
- 2013-03-12Phase 3 first posted: Mack Mitchell, Anakinra + Pentoxifylline (NCT01809132)
- 2012-11-02Phase 3 first posted: Pfizer's Upjohn has merged with Mylan to form Viatris Inc., placebo + iv sildenafil (NCT01720524)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision